Tectonic Therapeutic (TECX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 Jun, 2026Opening remarks and agenda
Meeting commenced at 9:00 A.M. on June 8, 2026, with polls opened for voting on all matters.
The meeting was held virtually and recorded for future reference.
Board members, executive officers, and the independent auditor were introduced.
The agenda included three proposals: election of directors, auditor ratification, and executive compensation.
Board and executive committee updates
Board members and executive officers present included François Nader, Praveen Tipirneni, Stefan Vitorovic, Tim Springer, Phil Dannenberg, Jessica Chutter, Dan Lochner, Marcella Ruddy, Peter McNamara, and Marc Schwabish.
Shareholder proposals
Three proposals were presented: election of two Class II directors, ratification of Deloitte & Touche LLP as auditor, and advisory vote on executive compensation.
Latest events from Tectonic Therapeutic
- TX45 demonstrated robust efficacy and safety in PH-HFpEF, targeting a large unmet need.TECX
TD Cowen 45th Annual Healthcare Conference30 Jun 2026 - TX45 and TX2100 advance as differentiated GPCR biologics for high-value, underserved markets.TECX
Investor presentation8 May 2026 - Q1 2026 net loss rose to $25.2M as R&D spending increased; cash runway extends into Q4 2028.TECX
Q1 20267 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.TECX
Proxy filing24 Apr 2026 - Director elections, auditor ratification, and executive pay are key items at the 2026 virtual meeting.TECX
Proxy filing24 Apr 2026 - TX45 and TX2100 advance in the clinic, with differentiated strategies and strong preclinical data.TECX
Leerink Global Healthcare Conference 202611 Mar 2026 - Advancing novel therapies for pulmonary hypertension and HHT, with pivotal data expected by 2027.TECX
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Strong cash position and advancing clinical pipeline, with key trial results expected in 2026.TECX
Q4 202526 Feb 2026 - TX2100 targets HHT with a novel, selective anti-angiogenic approach and strong preclinical results.TECX
KOL event24 Feb 2026